Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sevelda

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Wiener Klinische Wochenschrift|August 3, 1990
[The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma]P Sevelda, M Barrada, N Vavra, et al.
Archives of Gynecology and Obstetrics|January 1, 1993
Serum prostaglandin F2 alpha (PGFM) and oxytocin levels correlate with sonographic changes in the cervix in patients with preterm laborN Vavra, W Eppel, P Sevelda, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 1992
[The significance of prostaglandin F2 alpha (PGFM)--and plasma oxytocin level in patients with premature labor]N Vavra, P Sevelda, R Fitz, et al.
Breast Cancer Research and Treatment|March 11, 1998
Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculatureC Peters-Engl, M Medl, M Mirau, et al.
Anticancer Research|January 1, 1997
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patientsJ Fischer-Colbrie, A Witt, H Heinzl, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997
[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.
International Journal of Cancer|July 17, 1995
Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survivalA Obermair, C Kurz, K Czerwenka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.
Cancer Letters|April 30, 1990
Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Wiener Klinische Wochenschrift|August 3, 1990
[The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma]P Sevelda, M Barrada, N Vavra, et al.
Archives of Gynecology and Obstetrics|January 1, 1993
Serum prostaglandin F2 alpha (PGFM) and oxytocin levels correlate with sonographic changes in the cervix in patients with preterm laborN Vavra, W Eppel, P Sevelda, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 1992
[The significance of prostaglandin F2 alpha (PGFM)--and plasma oxytocin level in patients with premature labor]N Vavra, P Sevelda, R Fitz, et al.
Breast Cancer Research and Treatment|March 11, 1998
Color-coded and spectral Doppler flow in breast carcinomas--relationship with the tumor microvasculatureC Peters-Engl, M Medl, M Mirau, et al.
Anticancer Research|January 1, 1997
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patientsJ Fischer-Colbrie, A Witt, H Heinzl, et al.
Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997
[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.
International Journal of Cancer|July 17, 1995
Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survivalA Obermair, C Kurz, K Czerwenka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.
Cancer Letters|April 30, 1990
Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.
Pageof 15